Lawrence P. Carter, Ph.D.

Affiliations: 
Jazz Pharmaceuticals, Palo Alto, CA, United States 
Area:
Human behavioral pharmacology
Google:
"Lawrence Carter"
Mean distance: 16.17 (cluster 29)
 
SNBCP

Parents

Sign in to add mentor
Charles Patrick France grad student 2005 UT Health San Antonio
 (*Discriminative stimulus and behavioral effects of gamma-hydroxybutyrate.)
Roland Griffiths post-doc Johns Hopkins
Miriam Z. Mintzer post-doc 2005-2007 Johns Hopkins Medical School
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Carter LP, Henningfield JE, Wang YG, et al. (2018) A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. Journal of Psychopharmacology (Oxford, England). 269881118796814
Baladi MG, Forster MJ, Gatch MB, et al. (2018) Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. The Journal of Pharmacology and Experimental Therapeutics
Reissig CJ, Harrison JA, Carter LP, et al. (2015) Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology. 232: 871-83
Sheffer CE, Christensen DR, Landes R, et al. (2014) Delay discounting rates: a strong prognostic indicator of smoking relapse. Addictive Behaviors. 39: 1682-9
Carter L. (2013) Commentary on Nonnemaker et al. (2013): Banning menthol cigarettes - is it time to conduct the experiment? Addiction (Abingdon, England). 108: 179-80
Carter LP, Kleykamp BA, Griffiths RR, et al. (2013) Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers. Psychopharmacology. 226: 53-63
Carter LP, Reissig CJ, Johnson MW, et al. (2013) Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans. Drug and Alcohol Dependence. 128: 206-13
Carter LP, Reissig CJ, Johnson MW, et al. (2013) Corrigendum to Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans [Drug Alcohol Depend. 128 (2013) 206-213] Drug and Alcohol Dependence. 133: 294
Reissig CJ, Carter LP, Johnson MW, et al. (2012) High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology. 223: 1-15
Sheffer C, Mackillop J, McGeary J, et al. (2012) Delay discounting, locus of control, and cognitive impulsiveness independently predict tobacco dependence treatment outcomes in a highly dependent, lower socioeconomic group of smokers. The American Journal On Addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 21: 221-32
See more...